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Results: We have enrolled 13 men and 16 women, median age 65 years 
old. In 29 evaluable patients, only 1 episode of febrile neutropenia has 
been documented and was related to aspergillus pneumonia. Twenty of 
29 patients have developed grade 3/4 neutropenia (only 4 grade 4), all 
requiring dose reductions. Ten of 29 patients have developed grade 3/4 
thrombocytopenia, and an additional 11 of 29 had grade 1 or 2 throm-
bocytopenia. No signiﬁcant bleeding episodes have been documented, 
though grade 1/2 hemorrhoidal bleeding was documented in 4/29 and 
grade 1 hematuria occurred in 4/29 patients. Anemia has been mild 
with grade 3 anemia in only 5 of 29 patients. Non-hematologic toxicity 
was generally minor, with fatigue being the principal toxicity; adverse 
events possible related to BV include grade 3 hypertension and angina 
(1 pt), grade 1 hypertension (1 pt), perforated ulcer (1 pt) and epistaxis 
(grade 3 in 1 pt, grade 1 in 11 pts). No thrombosis has been reported 
and grade 1 proteinuria in only 1 patient. There have been no fatal 
toxicities. 
Conclusions: To date, the addition of BV to GC in pts with NSCLC is 
generally well tolerated, and toxicities have been expected and manage-
able. Enrollment is ongoing. 
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Background: It is apparent that there is a cluster of clinical factors that 
predict for an increased rate of response and survival to the epidermal 
growth factor (EGFR) tyrosine kinase inhibitors. However, the current 
knowledge of EGFR DNA mutations and gene expression is insuf-
ﬁcient to explain these observations. The purpose of this study is to 
enrich the population of patients more likely to respond to the EGFR 
inhibitor, erlotinib, and to perform extensive genomic screening to 
identify tumour-speciﬁc genome abnormalities to predict patterns of 
response and resistance. 
Methods: Eligibility criteria: stage IIIB/IV NSCLC; chemo-naive; ≥ 
1 measurable lesion; ECOG ≤2; adequate organ function; and at least 
2 of the following 4 criteria: women, never-smokers, Southeast Asian 
extraction, adenocarcinoma (ACA) and/or bronchioloalveolar carci-
noma. All patients must consent to a baseline fresh tumour biopsy and 
serum sample; biopsies during treatment and at disease progression are 
optional. Tumour cells are isolated by laser microdissection following a 
pathology review. Tumour genomic DNA is applied to high-resolution 
genomic microarrays to detect tumour-speciﬁc changes in copy number 
and/or genotype at multiple sites across the genome, including EGFR 
and exons encoding genes with altered copy number. Erlotinib 150mg 
p.o. daily is given on a continuous basis until disease progression.
Results: From Sept-06 to Feb-07, 20 patients (pts) have been enrolled. 
Median age 62 (range 43- 78); 17 females and 3 males; 18 never 
smokers, 2 former and 0 current smokers. PS 0-4; 1 - 13; 2 - 3. Ethnic-
ity: 5 Caucasian and 15 Asian (including China-7 & Hong Kong-3). 
Pathology: 17 ACA; 1 squamous carcinoma; 2 NSCLC NOS. As of 
Feb-07, 16 pts have received >8 weeks of treatment or have been taken 
off study for progressive disease. Toxicities consist of expected rates of 
rash and diarrhea. Responses: PR - 5; SD - 6; PD - 5; 4 pts are too early 
to assess (4 weeks only). Thus 11 of 16 (69%) have not progressed at 8 
weeks. All pts had fresh tumour samples collected. Laser microdissec-
tion and tumour DNA extraction was performed and genomic analysis 
is underway.
Summary: In this clinically selected population treated with ﬁrst-line 
erlotinib, the rate of non-progression at 8 weeks is acceptable. A unique 
correlation of extensive molecular data obtained from fresh tumour 
samples, data on pre-drug genetic abnormalities and post-drug clinical 
response, time to progression, and survival will be performed in all 
patients enrolled in this study. This work represents an effort to go 
beyond EGFR analysis and uncover novel features of the lung cancer 
genome that may help predict drug response and further understanding 
of tumour biology.
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Background: Geﬁtinib is a selective inhibitor of the epidermal growth 
factor (EGFR) tyrosine kinase and approved for use as salvage therapy 
in advanced non-small cell lung cancer (NSCLC). We retrospectively 
analyzed 359 Korean NSCLC patients treated with geﬁtinib to identify 
clinicopathologic parameters predictive of response and survival 
beneﬁt. 
Methods: Data from NSCLC patients treated with geﬁtinib at Samsung 
Medical Center in Korea from Jan 2003 until Dec 2005 were collected. 
Patients were treated with geﬁtinib 250mg per day until progression 
or development of toxicity. Response evaluation with spiral CT scan 
was performed at 4-8 weeks after geﬁtinib treatment. Multivariate Cox 
regression hazards analysis was performed to determine the combined 
effects of clinicopathological variables in relation to tumor response 
and overall survival.
Results: For 331 evaluable patients the overall response rate was 
25.1% (83/331; 3 CR, 80 PR) and disease control rate was 48.6%. 
Median age was 60 years (range 25-86). 236 patients (65.7%) were 
male and 154 patients (42.9%) were never-smokers. The most com-
mon histological subtype was adenocarcinoma (67.1%) and 183 
patients(51.0%) had a PS≥2. In a large majority of case (90.0%), 
cytotoxic chemotherapy had been administered before treatment of 
geﬁtinib and most of them received platinum-based combination 
regimens(84.4%) as the ﬁrst-line treatment. At a median follow-up of 
30 months, the median survival for all the 359 patients from the date 
of geﬁtinib administration was 6.2 months with 1 year-survival rate of 
32.2%. The median survival time calculated from the ﬁrst diagnosis of 
advanced/metastatic or recurrent disease was 19.7 months. Good per-
formance status (PS 0-1), never-smoker and development of skin rash 
after administration of geﬁtinib were statistically signiﬁcant favorable 
predictive markers for tumor response by multivariate analysis. Sig-
niﬁcant predictors for favorable survival were good performance status 
